YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Dostinex
Dostinex Linked to Heart Valve Disease
New Studies Link Dostinex to Serious Heart AilmentsOn January 3, 2007 new studies came out linking Dostinex with heart valve disease. A study by Italian researchers found that roughly one-fourth of Parkinson's patients taking Dostinex had moderate to severe heart valve troubles. An additional study by German doctors established that users of Dostinex were five to seven times more likely to have leaky heart valves than those on other types of Parkinson's medications. Both studies can be found in the New England Journal of Medicine.
In the Italian study, Dr. Renzo Zanettini and others at the Instituti Clinici di Perfezionamento in Milan obtained echocardiogram images of the hearts of 155 patients taking various Parkinson's medications and a comparison group of 90 healthy people. Moderate to severe valve problems were seen in 29% those on Dostinex. In the German study, Dr. Rene Schade and associates in Berlin and in Montreal used records from over 11,400 Parkinson's patients in the United Kingdom. The rate of newly diagnosed leaky valves was increased among Dostinex users.
Dostinex (generic: cabergoline) manufactured by Pfizer Inc., gained approval by the FDA on December 23, 1996. Dostinex is used for Parkinson’s in other countries but is approved in this country only for a hormonal disorder, hyperprolactinemia.
Dr. Michael Berelowitz, senior vice president of Pfizer, which makes Dostinex, said the company had received fewer than 100 reports of valve problems from the drug, mostly in people with Parkinson’s. The two new reports involve only Parkinson’s. The results should not be applied to patients who take Dostinex for the hormone disorder, because they take far smaller doses of the drug than do patients with Parkinson’s, said Dr. David L. Kleinberg, a professor of medicine and director of the neuroendocrine unit at New York University’s medical school. Many doctors consider it the best drug for the problem. People with Parkinson’s often take doses 20 to 40 times as high.
Dostinex sales in the United States totaled about $88 million in 2005, and about 87,000 prescriptions were written, according to Wolters Kluwer Health, an information company in the Netherlands.
Legal Rights for Dostinex Users
If you or a loved one took Dostinex and you suffered heart valve damage or any other serious side effects, please fill out the form at the right for a free case evaluation from a qualified defective drug attorney.
DostinexRSS Feed
Parkinson's drug pulled from market
Mar 29, 2007 | AP
A drug used by several thousand patients with Parkinson's disease is being pulled from the market because of reports of heart valve damage. The Food and Drug Administration said Thursday that pergolide, sold under the name Permax and also in generic versions, is being withdrawn at the agency's request. There are other drugs in the same class that can be substituted, Dr. Robert Temple of the FDA's office of drug evaluation said at a briefing. At least 14 patients have needed to have heart...
Parkinson's meds, valve risk linked
Jan 9, 2007 | AP
The risk of heart valve damage with two drugs for Parkinson’s disease may be far greater than was known, new research suggests. The drugs are not the main treatment for Parkinson’s, but one is also sometimes used to treat restless legs syndrome. A study by Italian researchers found that roughly one-fourth of Parkinson’s patients taking pergolide or cabergoline, sold as Permax, Dostinex and other brands, had moderate to severe heart valve problems. Another study, by German...
Parkinson's Drugs May Have More Risks
Jan 8, 2007 | AP
The risk of heart valve damage with two drugs for Parkinson's disease may be far greater than was known, new research suggests. The drugs are not the main treatment for Parkinson's, but one is also sometimes used to treat restless legs syndrome. A study by Italian researchers found that roughly one-fourth of Parkinson's patients taking pergolide or cabergoline, sold as Permax, Dostinex and other brands, had moderate to severe heart valve problems. Another study, by German doctors, found that...
Parkinsons Drugs May Lead to Heart Damage
Jan 4, 2007 | Newsinferno.com
Two new studies published in today’s New England Journal of Medicine have called into question the safety of two specific medications prescribed for Parkinson’s disease. The two drugs cited Valeant Pharmaceuticals’ Permax (pergolide) and Pfizer’s Dostinex (cabergoline) have been shown to lead to an increased risk of heart valve damage in Parkinson’s patients, but the new studies indicate that the risk of valve damage may be higher than previously thought. In the...
Two Parkinson's drugs linked to valve risk
Jan 4, 2007 | UPI
Two drugs used for Parkinson's disease increase the risk of heart-valve damage, studies said, prompting a U.S. official to call for a halt in their use. Patients who took pergolide or cabergoline are four to seven times as likely to suffer heart-valve damage as patients who did not, two studies in Thursday's New England Journal of Medicine found. Previous reports of heart-valve disease links led to the drugs being prescribed less frequently, the Wall Street Journal said. Manufacturers said the...
Dostinex
Quick Facts
Dostinex Reference Guide
Generic Name
Cabergoline
Date Approved
December 23, 1996
Manufacturer
Pfizer
Status
On the market
New Study 1/3/07
Approved Use in U.S.
Hyperprolactinemia
Approved Use in Europe
Parkinson’s disease
Serious Side Effects
Heart valve disease
Leaky valves
Heart damage
Cardiac valvulopathy
Heart valve damage
Related Topics
Permax
Heart Valve Disease
Parkinson's Disease
Defective Drugs
Diseases
Cabergoline
Date Approved
December 23, 1996
Manufacturer
Pfizer
Status
On the market
New Study 1/3/07
Approved Use in U.S.
Hyperprolactinemia
Approved Use in Europe
Parkinson’s disease
Serious Side Effects
Heart valve disease
Leaky valves
Heart damage
Cardiac valvulopathy
Heart valve damage
Related Topics
Permax
Heart Valve Disease
Parkinson's Disease
Defective Drugs
Diseases
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS
